SanFran,

You are confusing oncology with cardiovascular, and confusing Resverlogix with Zenith.

Resverlogix is developing their lead bromodomain-2 selective BET inhibitor apabetalone. Pretty much all other companies, including Constellation, in the BET inhibitor field are developing pan-BET inhibitors than bind to both bromodomains 1 and 2 without selectivity. Resverlogix has correctly and repeatedly claimed that they have a huge lead over any other company for 1) bromodomain selective BET inhibitors; and 2) BET inhibitors in the cardiovascular field. This is true. Except for apabetalone, no other BET inhibitor is in clinical trials for anything other than oncology. Furthermore, except for Abbvie's Phase 1 compound ABBV-744 for oncology, I don't think there is any other BD selective BET inhibitor in clinical trials other than apabetalone.

Constellation is more related to Zenith, since both are developing pan-BET inhibitors. Zenith has correctly and repeatedly claimed that they were coming from behind but are now tied with or in the lead with other pan-BET inhibitor companies like Constellation.

BDAZ